Home/Pipeline/Ritlecitinib (Litfulo)

Ritlecitinib (Litfulo)

Alopecia Areata

ApprovedCommercial

Key Facts

Indication

Alopecia Areata

Phase

Approved

Status

Commercial

Company

XOMA

About XOMA

XOMA has strategically transformed from a traditional drug developer into a capital-efficient royalty aggregator, building a diversified portfolio of economic interests in innovative therapeutic candidates. The company's model mitigates traditional biotech risks by acquiring rights to potential future payments from partnered programs, many of which are advanced by well-funded biopharma partners. XOMA's deep expertise in antibody science informs its investment decisions, targeting programs with validated biology and significant commercial potential across various therapeutic areas.

View full company profile

Therapeutic Areas

Ophthalmology Immunology Pain Rare Diseases Endocrinology

Other Alopecia Areata Drugs

Drug	Company	Phase	Status
Exploratory Asset	Veradermics	Exploratory/Pre-clinical	Future pipeline candidate
Rezpegaldesleukin	Nektar Therapeutics	Phase 2b	Active, not recruiting